PBM Kickback Prohibition Act

PBM Reform, transparency S. 1414, Expedited Access to Biosimilars Act - A bill to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. S.4189 - INSULIN Act of 2026 - A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin. H.R.7895 - PBM Kickback Prohibition Act - A bill to prohibit kickbacks to pharmacy benefit managers.

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $1,240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

House: H.R.1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14. H.R. 425, the Repealing Big Brother Overreach Act H.R.7035, the Credit Card Competition Act of 2026 H.R. 6213, the Heat Workforce Standards Act of 2025 H.R. 4776, the Standardizing Permitting and Expediting Economic Development (SPEED) Act H.R. 4366, the Save Local Business Act H.R. 3898, the Promoting Efficient Review for Modern Infrastructure Today (PERMIT) Act H.R. 3699, the Energy Choice Act H.R. 4424, the Securing Help for Involuntary Employment Loss and Displacement (SHIELD) Act H.R. 5463, the Custom Health Option and Individual Care Expense (CHOICE) Arrangement Act H.R.6703, the Lower Health Care Premiums for All Americans Act H.R. 20, the Richard L. Trumka Protecting the Right to Organize (PRO) Act H.R. 4896, the Warehouse Worker Protection Act H.R. 2743, the Raise the Wage Act H.R. 1319, the Modern Worker Empowerment Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 5349, the Tax Court Improvement Act H.R. 5346, the Fair and Accountable IRS Review Act H.R.5267, the American Franchise Act H.R. 2528, the Association Health Plans Act H.R. 6420, the Affordable Care Economic Stability and Small Business (ACCESS) Act H.R.1163, the Prove It Act of 2025 H.R. 5258, the Lawsuit Abuse Reduction Act of 2025 H.R. 2675, the Protecting Our Courts from Foreign Manipulation Act of 2025 H.R. 4626, the Home Appliance Protection and Affordability Act H.R.7148 - Consolidated Appropriations Act, 2026 H.R.7328 - Protecting Small Businesses from Predatory Website Lawsuits Act H.R. 6250, the Cold Weather Diesel Reliability Act of 2025 H.R. 6453, the Americans with Disabilities Act 30 Days to Comply Act H.R.7847, the Stop Unemployment Fraud Act H.R. 2528, the Association Health Plans Act H.R. 8082, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act H.R. 6538, the More Affordable Care Act H.R. 5582, the Patients Deserve Price Tags Act H.R. 5408, the Faster Labor Contracts Act H.R.8800, National Defense Authorization Act for Fiscal Year 2027 H.R.3269, Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 5337, Motor Carrier Safety Selection Standard Act Consumer Financial Protection Bureau Section 1071 rule requires covered financial institutions to collect and report demographic and credit data on small business loan applications. H.R. 8415, Small Business Tax Cut Act H.R. 1897, Endangered Species (ES) Amendments Act of 2025 H.R.5166, Financial Services and General Government Appropriations Act, 2026 H.R. 1687, the Committing Leases for Energy Access Now (CLEAN) Act H.R. 6398, the Reducing and Eliminating Duplicative Environmental Regulations Act H.R. 8414, Know Your Labor Rights Act H.R. 7861, HSAs for All Act H.R. 7895, PBM Kickback Prohibition Act H.R. 9618, Diesel Engine Flexibility Act H.R. 9340, Ratepayer Protection Act H.R.1515, Guidance Out of the Darkness (GOOD) Act H.R. 10015, Great American Healthcare Act H.R. 5883, Safer Supervision Act of 2025 H.R. 1501, the Protecting Domestic Mining Act H.R. 9618, the Diesel Engine Flexibility (DEF) Act H.R. 10263, Halt Abusive Internet Lawsuits Act of 2026 H.R. 2675, the Protecting Our Courts from Foreign Manipulation H.J. Res. 210, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision", which would repeal an Environmental Protection Agency (EPA) rule requiring ocean-going vessels to reduce emissions while docked at California ports that increased shipping costs for energy, consumer products and inputs, and increased electricity demand and costs for small businesses and consumers. H.J. Res 213, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule issued by the Environmental Protection Agency relating to the "California State Nonroad Engine Pollution Control Standards; Commercial Harbor Craft Regulations; Notice of Decision", which would repeal the Environmental Protection Agencys (EPA) "California State Nonroad Engine Pollution Control Standards; Commercial Harbor Craft Regulations; Notice of Decision" rule which mandated that harbor vessels install more expensive zero-emissions engines. This regulation increased operating and energy costs for small businesses and consumers in California and across the country Issues relating to small business taxation Issues related to the expiring TCJA tax provisions Issues related to ADA website reforms Issues related to the minimum wage increase Issues related to "Affordable Care Act Reform" Issues related to Pharmacy Benefit Managers Issues related to Health Reform Issues related to regulatory reforms Issues related to Waters of United State Senate: S. 100, the Repealing Big Brother Overreach Act S.3623, the Credit Card Competition Act of 2026 S. 4427, Heat Workforce Standards Act of 2026 S. 3117, the Worker Reforming Elections for Speedy and Unimpeded Labor Talks (RESULTS) Act S. 3116, the Fairness in Filing Act S. 5213, the Union Members' Right to Know Act S.3124, the Protection on the Picket Line Act S.3128, the Worker Privacy Act S. 852, the Richard L. Trumka Protecting the Right to Organize (PRO) Act S. 2613, the Warehouse Worker Protection Act S. 844, the Faster Labor Contracts Act S. 2013, the Higher Wages for American Workers Act S. 1332, the Raise the Wage Act S. 1945, the Energy Choice Act S. 1379, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act S.2875, the Custom Health Option and Individual Care Expense (CHOICE) Act S. 1847, the Association Health Plans Act S. 3418, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act S.495, Prove it Act of 2025 S. 3264, the More Affordable Care Act S. 2355, the Patients Deserve Price Tags Act S. 4366, Know Your Labor Rights Act S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act S. 4419: A bill to amend title 31, United States Code, to require only foreign entities to report beneficial ownership information, and for other purposes. S.J. Res. 208, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle Pollution Control Standards; Advanced Clean Car Program; Reconsideration of a Previous Withdrawal of a Waiver of Preemption; Notice of Decision", which would repeal an Environmental Protection Agency (EPA) waiver granted to the California Air Resources Board (CARB), allowing the continuation of the Advanced Clean Cars (ACC) framework. These overreaching standards would have resulted in a costly and unrealistic electric vehicle mandate on small business owners and consumers nationwide. S.J. Res. 209, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Ocean-Going Vessels At-Berth; Notice of Decision" which would repeal an Environmental Protection Agency (EPA) rule requiring ocean-going vessels to reduce emissions while docked at California ports. Issue relating to small business taxation S.J. Res. 206, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle Pollution Control Standards; Notice of Decision Granting a Waiver of Clean Air Act Preemption for California's 2009 and Subsequent Model Year Greenhouse Gas Emission Standards for New Motor Vehicles" which would repeal an Environmental Protection Agency (EPA) rule titled California State Motor Vehicle Pollution Control Standards; Notice of Decision Granting a Waiver of Clean Air Act [CAA] Preemption for California's 2009 and Subsequent Model Year Greenhouse Gas Emission Standards for New Motor Vehicles that increased the cost of vehicles for small businesses and consumers. S.J. Res. 207, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle Pollution Control Standards; Notice of Decision Granting a Waiver of Clean Air Act Preemption for California's Advanced Clean Car Program and a Within the Scope Conformation for California's Zero Emission Vehicle Amendments for 2017 and Earlier Model Years" which would repeal the Environmental Protection Agencys (EPA) waiver granting the California Air Resources Board (CARB) the authority to create the Advanced Clean Cars (ACC) framework. This overreaching rule increased costs for small businesses and consumers by creating a de facto electric vehicle mandate. S.J. Res. 205, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Nonroad Engine Pollution Control Standards; Small Off-Road Engines Regulations; Notice of Decision" which would repeal the Environmental Protection Agencys (EPA) rule titled "California State Nonroad Engine Pollution Control Standards; Small Off-Road Engines [SORE] Regulations. Issue related to the expiring TCJA tax provisions Issue related to ADA website reforms Issue related to the minimum wage increase Issue related to "Affordable Care Act Reform" Issue related to Pharmacy Benefits Managers Issue related to Health reform Issues related to wiretapping and eavesdropping law abuse Department of the Treasury: Beneficial Ownership Information (BOI) Reporting Rule White House: Beneficial Ownership Information (BOI) Reporting Rule Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Short-Term, Limited-Duration Insurance Plans Issues related to Health Savings Accounts Issues related to CHOICE Arrangements Healthcare Transparency Rule Vice President of the U.S.: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Department of Labor: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Short-Term, Limited-Duration Insurance Plans Occupational Safety and Health Administration: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Small Business Administration: Beneficial Ownership Information (BOI) Reporting Rule Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Title III ADA website reforms Department Health and Human Services: Short-Term, Limited Duration Insurance Rule Individual Coverage Health Reimbursement Arrangement Rule Health Savings Account Rule

Client expense: $1,910,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Occupational Safety & Health Administration (OSHA), SENATE, Small Business Administration (SBA), Treasury, Dept of, Vice President of the U.S., White House Office

HJRes 197 / SJRes 197, CRA related to the 2027 NBPP; HR 247 / S 46, Health Care Affordability Act; HR 6867 / S 3562, the NIH Clinical Trial Integrity Act; HR 3521 / S 4440, the Clinical Trial Modernization Act; HR 4710 / S 2420, No Surprises Act Enforcement Act; HR 5526 / S 1954, Biosimilar Red Tape Elimination Act; HR 5582 / S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8879 / S 4509, Patients Before Monopolies Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act; HR 9396, the Prior Authorization Accountability Act; HR 9397, the Premium Transparency Act; HR 9645, the Health Care Price Certainty for All Americans Act; HR 9661 / S 1414, the Expedited Access to Biosimilars Act; HR 10370, the AIM to Cure Kids with Cancer Act; HR 10788, the Lower Premiums, Faster Payments Act; S 976, the Insurance Fraud Accountability Act; S 1041, Affordable Prescriptions for Patients Act; S 1095, Stop STALLING Act; S 1096, Preserve Access to Affordable Generics & Biosimilars Act S 1097, Interagency Patent Coordination & Improvements Act; S 2658, Medication Affordability & Patent Integrity Act; S 3014, Ensuring Timely Access to Generics Act; S 3822, the Break Up Big Medicine Act Policies to address the expiration of the enhanced Advanced Premium Tax Credits; Policies to improve transparency in hospital and insurer costs and finances; Policies to streamline pediatric patient access to subspecialist care via telemedicine; Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance; Policies related to modernization of clinical trials; Policies related to the 2027 FDA user fee agreements; Implementation of the No Surprises Act; Policies related to oversight of insurance agents and brokers; Oversight and patient impact of the 340B program; Policies related to consolidation within the healthcare sector;

Client expense: $120,000 · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Issues related to commercial insurance and pharmacy benefits. H.R.4710: No Surprises Act. H.R.7895: PBM Kickback Prohibition Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S.2276/ H.R. 3269; Eliminating Thickets to Improve Competition Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,203,049 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)

Issues related to the implementation of the Patient Protection and Affordable Care Act (PL 111-148). H.R. 5463 - CHOICE Arrangement Act, S. 2875 - Custom Health Option and Individual Care Expense (CHOICE) Act: Provisions related to Health Reimbursement Arrangements. H.R. 8324 - Great American Healthcare Plan: Provisions related to Health Savings Accounts. H.R. 7895 - PBM Kickback Prohibition Act: Provisions related to prescription drugs.

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.3251/S 4440 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement -Update CMS Long stay antipsychotic Quality measure -Update FDA Antipsychotic black box warning -Funding for NIH (HR 9260) -PASTEUR Act (HR 7352/S 4975) -Biosimilar Access and Affordability Act (HR10628/S5571) -CMS Fixed Dose Combination Therapies proposed policy -OMB Proposed Uniform Guidance on Federal Grantmaking (HR 6500) -Alzheimer's Early Detection Act (HR 9823) -CMS reporting requirements for Medicare Prescription Payment Program (HR 9260) -CMS Trans Catheter Aortic Valve Replacement NCD proposal

Client expense: $65,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Affordable Care Act and Extending Enhanced APTCs (H.R. 247; S. 46), Individual Market/ACA exchanges; Fraudulent Enrollments in Qualified Health Plans (S. 976, HR 2079), Behavioral Health, Employer-Provided Health Coverage; Surprise Billing (S. 2420, H.R. 4710); Cybersecurity; Health IT, Health Care Innovation, Transparency & PBMs (S. 891, H.R. 6703), PBM Compensation (H.R. 7895), Prescription Drugs (S. 1954, S. 1096, S.1040), Price Transparency (S. 2355, H.R. 9393, H.R. 9397, H.R. 9645, H.R. 9390), Prior Authorization (H.R. 9396), 340B, Insulin (S. 4189), Corporate Practice of Medicine, Anticompetitive Contracting (H.R. 6248, S. 4027).

Client expense: $670,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE

H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.43 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Sen. Hickenlooper, John W. [D-CO] H.R.6485 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Rep. Cline, Ben [R-VA-6] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

HR 247 / S 46, Health Care Affordability Act; S 2420, No Surprises Act Enforcement Act; HR 3521, the Clinical Trial Modernization Act; HR 5526, Biosimilar Red Tape Elimination Act; HR 5582, S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act; HR 9396, the Prior Authorization Accountability Act; HR 9397, the Premium Transparency Act; HR 9661, Expedited Access to Biosimilars Act; S 1041, Affordable Prescriptions for Patients Act; S 1095, Stop STALLING Act; S 1096, Preserve Access to Affordable Generics & Biosimilars Act S 1097, Interagency Patent Coordination & Improvements Act; S 2658, Medication Affordability & Patent Integrity Act; S 3014, Ensuring Timely Access to Generics Act; S 4509, Patients Before Monopolies Act; Policies to address the expiration of the enhanced Advanced Premium Tax Credits; Policies to improve transparency in hospital and insurer costs and finances; Policies to streamline pediatric patient access to subspecialist care via telemedicine; Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance; Policies related to the modernization of clinical trials; Policies related to the 2027 FDA user fee agreements; Implementation of the No Surprises Act; Policies related to oversight of insurance agents and brokers; Oversight and patient impact of the 340B program;

Client expense: $590,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to the impact of pharmacy benefit manager (PBM) practices on employer-sponsored health care/ERISA, Medicare, Medicaid, and Tricare PBM Kickback Prohibition Act (H.R. 7895)

Client expense: $584,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

4-16 Employer Groups Applaud House Funding Bill that Includes PBM Reform 4-20 support for the PBM Kickback Prohibition Act (H.R. 7895) 6-24 support for the Health Data Access, Transparency, and Affordability Act of 2026 (H.R. 9228)

Client expense: Not reported · Firm income: $270,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to PBM transparency and reporting (HR 7895), broker compensation transparency, and employer requirements established as result of COVID-19.

Client expense: $350,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE

Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.43 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Sen. Hickenlooper, John W. [D-CO] H.R.6485 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Rep. Cline, Ben [R-VA-6] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $990,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to commercial insurance and pharmacy benefits. H.R.4710: No Surprises Act. H.R.7895: PBM Kickback Prohibition Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Affordable Care Act and Extending Enhanced APTCs (H.R. 247; S. 46), 2026 Proposed NBPP/Individual Market/ACA exchanges; Fraudulent Enrollments in Qualified Health Plans (S. 976, HR 2079), Behavioral Health, Employer-Provided Health Coverage; Surprise Billing (S. 2420, H.R. 4710); Cybersecurity; Health IT, Health Care Innovation, Transparency & PBMs (S. 891, H.R. 6703), PBM Compensation (H.R. 7895), Prescription Drugs (S. 1954, S. 1096, S. 1096, S.1040) Price Transparency (S. 2355, H.R. 9393, H.R. 9397), Prior Authorization (H.R. 9396), 340B.

Client expense: $700,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.43 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Sen. Hickenlooper, John W. [D-CO] H.R.6485 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Rep. Cline, Ben [R-VA-6] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $20,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

House: H.R.1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14. H.R. 425, the Repealing Big Brother Overreach Act H.R.7035, the Credit Card Competition Act of 2026 H.R. 6213, the Heat Workforce Standards Act of 2025 H.R. 4776, the Standardizing Permitting and Expediting Economic Development (SPEED) Act H.R. 4366, the Save Local Business Act H.R. 3898, the Promoting Efficient Review for Modern Infrastructure Today (PERMIT) Act H.R. 3699, the Energy Choice Act H.R. 4424, the Securing Help for Involuntary Employment Loss and Displacement (SHIELD) Act H.R. 5463, the Custom Health Option and Individual Care Expense (CHOICE) Arrangement Act H.R.6703, the Lower Health Care Premiums for All Americans Act H.R. 20, the Richard L. Trumka Protecting the Right to Organize (PRO) Act H.R. 4896, the Warehouse Worker Protection Act H.R. 2743, the Raise the Wage Act H.R. 1319, the Modern Worker Empowerment Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 5349, the Tax Court Improvement Act H.R. 5346, the Fair and Accountable IRS Review Act H.R.5267, the American Franchise Act H.R. 2528, the Association Health Plans Act H.R. 6420, the Affordable Care Economic Stability and Small Business (ACCESS) Act H.R.1163, the Prove It Act of 2025 H.R. 5258, the Lawsuit Abuse Reduction Act of 2025 H.R. 2675, the Protecting Our Courts from Foreign Manipulation Act of 2025 H.R. 4626, the Home Appliance Protection and Affordability Act H.R.7148 - Consolidated Appropriations Act, 2026 H.R.7328 - Protecting Small Businesses from Predatory Website Lawsuits Act H.R. 6250, the Cold Weather Diesel Reliability Act of 2025 H.R. 6453, the Americans with Disabilities Act 30 Days to Comply Act H.R.7847, the Stop Unemployment Fraud Act H.R. 2528, the Association Health Plans Act H.R. 8082, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act H.R. 6538, the More Affordable Care Act H.R. 5582, the Patients Deserve Price Tags Act H.R. 5408, the Faster Labor Contracts Act H.R.8800, National Defense Authorization Act for Fiscal Year 2027 H.R.3269, Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 5337, Motor Carrier Safety Selection Standard Act Consumer Financial Protection Bureau Section 1071 rule requires covered financial institutions to collect and report demographic and credit data on small business loan applications. H.R. 8415, Small Business Tax Cut Act H.R. 1897, Endangered Species (ES) Amendments Act of 2025 H.R.5166, Financial Services and General Government Appropriations Act, 2026 H.R. 1687, the Committing Leases for Energy Access Now (CLEAN) Act H.R. 6398, the Reducing and Eliminating Duplicative Environmental Regulations Act H.R. 8414, Know Your Labor Rights Act H.R. 8415, Small Business Tax Cuts Act of 2026 H.R. 7861, HSAs for All Act H.R. 7895, PBM Kickback Prohibition Act Issues relating to small business taxation Issues related to the expiring TCJA tax provisions Issues related to ADA website reforms Issues related to the minimum wage increase Issues related to "Affordable Care Act Reform" Issues related to Pharmacy Benefit Managers Issues related to Health Reform Issues related to regulatory reforms Senate: S. 100, the Repealing Big Brother Overreach Act S.3623, the Credit Card Competition Act of 2026 S. 4427, Heat Workforce Standards Act of 2026 S. 3117, the Worker Reforming Elections for Speedy and Unimpeded Labor Talks (RESULTS) Act S. 3116, the Fairness in Filing Act S. 5213, the Union Members' Right to Know Act S.3124, the Protection on the Picket Line Act S.3128, the Worker Privacy Act S. 852, the Richard L. Trumka Protecting the Right to Organize (PRO) Act S. 2613, the Warehouse Worker Protection Act S. 844, the Faster Labor Contracts Act S. 2013, the Higher Wages for American Workers Act S. 1332, the Raise the Wage Act S. 1945, the Energy Choice Act S. 1379, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act S.2875, the Custom Health Option and Individual Care Expense (CHOICE) Act S. 1847, the Association Health Plans Act S. 3418, the Competition and Openness in Markets to Promote Efficiency, Transparency, and Enhanced Affordability (COMPETE) Act S.495, Prove it Act of 2025 S. 3264, the More Affordable Care Act S. 2355, the Patients Deserve Price Tags Act S. 4366, Know Your Labor Rights Act S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act S. 4419: A bill to amend title 31, United States Code, to require only foreign entities to report beneficial ownership information, and for other purposes. Issue relating to small business taxation Issue related to the expiring TCJA tax provisions Issue related to ADA website reforms Issue related to the minimum wage increase Issue related to "Affordable Care Act Reform" Issue related to Pharmacy Benefits Managers Department of the Treasury: Beneficial Ownership Information (BOI) Reporting Rule H.R.1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14. White House: Beneficial Ownership Information (BOI) Reporting Rule Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues relating to the right to repair Office of Management and Budget: Beneficial Ownership Information (BOI) Reporting Rule H.R.7035/S.3623, the Credit Card Competition Act of 2026 H.R. 1566/S. 1379, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to Short-Term Limited Duration Insurance Plans Financial Crimes Enforcement Network: Beneficial Ownership Information (BOI) Reporting Rule Department of Health and Human Services: Issues related to Individual Coverage Health Reimbursement Arrangements (ICHRA) Regulation Reform Department of Labor: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule Issues related to General Health Care Reform Occupational Safety and Health Administration: Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings Rule

Client expense: $1,670,000 · Firm income: Not reported

Government targets: Financial Crimes Enforcement Network (FinCEN), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $276,347 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

PBM Reform, transparency H.R. 6703 - Lower Health Care Premiums for All Americans Act - A bill to ensure access to affordable health insurance. S.4189 - INSULIN Act of 2026 - A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin. H.R.7895 - PBM Kickback Prohibition Act - A bill to prohibit kickbacks to pharmacy benefit managers.

Client expense: $230,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act; H.R. 4409, the Fair Pharmacies for Federal Employees Act; S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act; H.R.7148, the Consolidated Appropriations Act of 2026; Rural Health Transformation Program; Creation and Implementation of TrumpRx; Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs; Request for Information"; S.3822, Break up Big Medicine Act; Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism"; Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]"; Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool; H.R. 7895, the PBM Kickback Prohibition Act; Comments to FDA on their comment request "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products [FDA-2025-N-6869]"; H.R.6509/S.3794, the SAFE Drug Act; H.R.5316, the Drug Shortage Compounding Patient Access Act; H.R.8779/S.4509, the Patients Before Monopolies Act; S.3788/H.R.8269, the CLEAR LABELS Act; S.1941, the Cure Hepatitis C Act of 2025;

Client expense: $270,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT)

S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025; Comments to Department of Labor RE: "Re: Reforming Pharmacy Benefit Manager (PBM) Compensation Practices"; H.R.7895, the PBM Kickback Prohibition Act; Comments to DOL on "Re: Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure [RIN 1210-AB37]"' Comments to DOJ on "Re: NCPA Comment on Competitor Collaboration Guidance (Docket No. ATR-2026- 0001)"' H.R.8779/S.4509, the Patients Before Monopolies Act;

Client expense: $270,000 · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE

-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -Message support for Rare Disease Clinical Trials Improvements

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $2,996,995 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)

Issues related to commercial insurance and pharmacy benefits. H.R.4710: No Surprises Act. H.R.7895: PBM Kickback Prohibition Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act; H.R. 4409, the Fair Pharmacies for Federal Employees Act; S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act; H.R.7148, the Consolidated Appropriations Act of 2026; Rural Health Transformation Program; Creation and Implementation of TrumpRx; Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs; Request for Information"; S.3822, Break up Big Medicine Act; Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism"; Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]"; Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool; H.R. 7895, the PBM Kickback Prohibition Act; Comments to FDA on their comment request "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products [FDA-2025-N-6869]";

Client expense: $320,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $299,699 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)